PMID- 20951295
OWN - NLM
STAT- MEDLINE
DCOM- 20110324
LR  - 20191210
IS  - 1878-3554 (Electronic)
IS  - 0099-2399 (Linking)
VI  - 36
IP  - 11
DP  - 2010 Nov
TI  - Effects of fibroblast growth factor-2 on the expression and regulation of 
      chemokines in human dental pulp cells.
PG  - 1824-30
LID - 10.1016/j.joen.2010.08.020 [doi]
AB  - BACKGROUND: Fibroblast growth factor-2 (FGF-2) participates in both hematopoiesis 
      and osteogenesis; however, the effects of FGF-2 on chemokines during 
      odontoblastic differentiation have not been reported. This study investigated 
      whether human dental pulp cells (HDPCs) treated with FGF-2 could express 
      chemokines during differentiation into odontoblastic cells and sought to identify 
      its underlying mechanism of action. METHODS: To analyze differentiation, we 
      measured alkaline phosphatase (ALP) activity, calcified nodule formation by 
      alizarin red staining, and marker RNA (mRNA) expression by reverse-transcriptase 
      polymerase chain reaction (RT-PCR). Expression of chemokines, such as 
      interleukin-6 (IL-6), IL-8, monocyte chemoattractant protein-1 (MCP-1), 
      macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-3alpha, were evaluated by 
      RT-PCR. RESULTS: ALP activity, the mineralization, and mRNA expression for 
      odontoblastic markers were enhanced by FGF-2 in HDPCs. FGF-2 also up-regulated 
      the expression of IL-6, IL-8, MCP-1, MIP-1alpha, and MIP-3alpha mRNAs, which were 
      attenuated by inhibitors of p38, ERK1/2 and p38 MAP kinases, protein kinase C, 
      phosphoinositide-3 kinase, and NF-kappaB. CONCLUSION: Taken together, these data 
      suggest that FGF-2 plays a role not only as a differentiation inducing factor in 
      the injury repair processes of pulpal tissue but also as a positive regulator of 
      chemokine expression, which may help in tissue engineering and pulp regeneration 
      using HDPCs. However, the fate of odontoblastic or osteoblastic differentiation, 
      effective local delivery for FGF-2, interaction of chemotatic and odontogenic 
      factors, and other limitations will need to be overcome before a major modality 
      for the treatment of pulp disease.
CI  - Copyright (c) 2010 American Association of Endodontists. Published by Elsevier Inc. 
      All rights reserved.
FAU - Kim, Young-Suk
AU  - Kim YS
AD  - Department of Oral and Maxillofacial Pathology, School of Dentistry and Institute 
      of Wonkwang Dental Research, Wonkwang University, Iksan, South Korea.
FAU - Min, Kyung-San
AU  - Min KS
FAU - Jeong, Dong-Ho
AU  - Jeong DH
FAU - Jang, Jun-Hyeog
AU  - Jang JH
FAU - Kim, Hae-Won
AU  - Kim HW
FAU - Kim, Eun-Cheol
AU  - Kim EC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Endod
JT  - Journal of endodontics
JID - 7511484
RN  - 0 (Anthraquinones)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL20)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Chemokines)
RN  - 0 (Coloring Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Genetic Markers)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (NF-kappa B)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 60MEW57T9G (alizarin)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
MH  - Alkaline Phosphatase/analysis
MH  - Anthraquinones
MH  - Calcification, Physiologic/drug effects
MH  - Cell Differentiation/drug effects
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - Chemokine CCL2/analysis
MH  - Chemokine CCL20/analysis
MH  - Chemokine CCL3/analysis
MH  - Chemokines/*drug effects
MH  - Coloring Agents
MH  - Dental Pulp/cytology/*drug effects/immunology
MH  - Enzyme Inhibitors/pharmacology
MH  - Fibroblast Growth Factor 2/*pharmacology
MH  - Gene Expression Regulation/drug effects
MH  - Genetic Markers/genetics
MH  - Humans
MH  - Interleukin-6/analysis
MH  - Interleukin-8/analysis
MH  - NF-kappa B/antagonists & inhibitors
MH  - Odontoblasts/drug effects
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinase C/antagonists & inhibitors
MH  - RNA/analysis
MH  - Signal Transduction/drug effects
MH  - Stem Cells/drug effects
MH  - Up-Regulation/drug effects
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
EDAT- 2010/10/19 06:00
MHDA- 2011/03/25 06:00
CRDT- 2010/10/19 06:00
PHST- 2010/04/22 00:00 [received]
PHST- 2010/07/26 00:00 [revised]
PHST- 2010/08/06 00:00 [accepted]
PHST- 2010/10/19 06:00 [entrez]
PHST- 2010/10/19 06:00 [pubmed]
PHST- 2011/03/25 06:00 [medline]
AID - S0099-2399(10)00678-3 [pii]
AID - 10.1016/j.joen.2010.08.020 [doi]
PST - ppublish
SO  - J Endod. 2010 Nov;36(11):1824-30. doi: 10.1016/j.joen.2010.08.020.